TABLE 3.
Subgroup analysis.
| Subgroup | WMD (95% CI) | I2 (%) | p value |
|---|---|---|---|
| Mean percent change of BMD in lumbar spine | |||
| Combination therapy vs. denosumab monotherapy | 3.57 (2.35, 4.79) | 32.30 | 0.000 |
| Combination therapy vs. teriparatide monotherapy | 2.00 (0.59, 3.42) | 28.70 | 0.006 |
| Mean percent change of BMD in hip | |||
| Combination therapy vs. denosumab monotherapy | 2.28 (1.53, 3.03) | 36.90 | 0.000 |
| Combination therapy vs. teriparatide monotherapy | 4.10 (3.30, 4.90) | 0.00 | 0.000 |
| Mean percent change of CTX in serum | |||
| Combination therapy vs. denosumab monotherapy | 3.19 (−8.32, 14.71) | 87.50 | 0.587 |
| Combination therapy vs. teriparatide monotherapy | −116.50 (−137.90, −95.11) | 0.00 | 0.000 |
BMD, Bone Mineral Density; CTX, Serum β-C-terminal telopeptide of type 1 collagen; CI, Confidence Interval.